Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

SGLT-2

This page shows the latest SGLT-2 news and features for those working in and with pharma, biotech and healthcare.

AZ’s Farxiga has no significant benefit for hospitalised COVID-19 patients

AZ’s Farxiga has no significant benefit for hospitalised COVID-19 patients

AstraZeneca’s (AZ) SGLT-2 inhibitor Farxiga showed no significant benefit for hospitalised COVID-19 patients, according to new detailed results presenting at the annual American College of Cardiology (ACC) meeting. ... Initially, Farxiga was approved

Latest news

  • NICE recommends MSD’s diabetes drug Steglatro NICE recommends MSD’s diabetes drug Steglatro

    drug. Steglatro is one of the competitors in the sodium-glucose cotransporter-2 (SGLT-2) inhibitor drugs, which are now becoming standard therapy in managing type 2 diabetes (T2D) patients in ... In the UK, the treatment is priced at £29.40 for 28 days,

  • The year of the blockbuster The year of the blockbuster

    The diseases targeted by the report’s projected market entrants include type 2 diabetes, endometriosis, childhood epilepsy, haemophilia, HIV, migraine, opioid addiction and shingles. ... Steglatro (ertugliflozin) from Pfizer and Merck:Sodium glucose

  • Novo’s diabetes pill defeats Merck’s Januvia in trial Novo’s diabetes pill defeats Merck’s Januvia in trial

    PIONEER 4 saw the enrolment of 711 people with type 2 diabetes inadequately controlled on metformin, or without an SGLT-2 inhibitor. ... Patients achieved a 4.7 and 5.0kg loss compared to 3.2 and 3.1kg with Victoza and 0.7 and 1.2kg with placebo.

  • FDA panel backs CV claims for Novo Nordisk's Victoza FDA panel backs CV claims for Novo Nordisk's Victoza

    The positive vote from EMDAC puts us one step closer to expanding our offering to reduce the risk of cardiovascular events in people with type 2 diabetes.". ... Victoza is the second drug to get a recommendation for improving cardiovascular outcomes in

  • AZ gets US approval for diabetes combo Qtern AZ gets US approval for diabetes combo Qtern

    The US FDA has approved AstraZeneca's Qtern, a two-drug therapy for type 2 diabetes, after rejecting the drug in 2015. ... The approval of Qtern is good news for patients who may benefit from improved glycaemic control by adding a DPP-4 inhibitor to a

More from news
Approximately 7 fully matching, plus 28 partially matching documents found.

Latest Intelligence

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    Rybelsus is available in the US to improve glycaemic control in adults with type 2 diabetes. ... It faces competition from entrenched generic metformin and sulphonylureas, as well as from more novel drug classes, particularly SGLT-2, inhibitors, DDP4

  • Leading AstraZeneca’s return to growth in Europe Leading AstraZeneca’s return to growth in Europe

    This is the first large real-world evidence study of its kind, evaluating the risk of hospitalisation for heart failure and death from any cause in patients with type 2 diabetes ... receiving treatment with SGLT-2 inhibitors, including AstraZeneca’s

  • Deal Watch November 2015 Deal Watch November 2015

    2, 700. Cardioxyl Pharmaceuticals. Bristol-Myers Squibb. Acquisition - company. Lead asset: p2  CXL-1427, nitroxyl (HNO) donor (prodrug) - iv treatment for acute decompensated heart failure (ADHF). ... 2, 075. Lexicon Pharmaceuticals. Sanofi.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
foxandcat.online

some pressure is helpful but too much of the wrong sort quickly takes its toll. we help creatove agenices manage...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...

Quick links